Fig. 4From: Modeling and simulation of maintenance treatment in first-line non-small cell lung cancer with external validationPosterior predictive check of HR in SATURN (a) and ATLAS (b) for maintenance erlotinib compared to placebo and simulation of HR in AVAPERL (c) for maintenance pemetrexed vs. placebo and comparison to observed HR. CI: confidence interval. HR: hazard ratio. PI: prediction intervalBack to article page